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ABSTRACT
Introduction. In 2008, the Movement Disorders Society (MDS) published a new Unified Parkinson’s Disease Rating Scale (MDS-
-UPDRS) as the official benchmark scale for Parkinson’s Disease (PD). We have translated and validated the Polish version of the 
MDS-UPDRS, explored its dimensionality, and compared it to the original English one.
Methods. The MDS-UPDRS was translated into Polish by a team of Polish investigators led by JS and GO. The back-translation 
was completed by colleagues fluent in both languages (Polish and English) who were not involved in the original translation, 
and was reviewed by members of the MDS Rating Scales Programme. Then the translated version of the MDS-UPDRS underwent 
cognitive pretesting, and the translation was modified based on the results. The final translation was approved as the Official 
Working Document of the MDS-UPDRS Polish version, and was tested on 355 Polish PD patients recruited at movement disor-
ders centres all over Poland (at Katowice, Gdańsk, Łódź, Warsaw, Wrocław, and Kraków). Confirmatory and explanatory factor 
analyses were applied to determine whether the factor structure of the English version could be confirmed in the Polish version.
* translation/back-translation team members 
** Task Force members in alphabetical order: Andrzej Bogucki8, Piotr Janik6, Magdalena Koszewicz3, Marta Leńska-Mieciek7,  
Małgorzata Michałowska7, Marta Piaścik-Gromada7, Katarzyna Potasz-Kulikowska10, Marek Śmiłowski1*, Anna Wasielewska16,  
Magdalena Wójcik-Pędziwiatr11
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Introduction
Parkinson’s Disease (PD) is a progressive, incurable, 
neurodegenerative disease presenting with motor and non-
-motor symptoms. There is no ideal biomarker to determine 
disease severity, and many different clinical, laboratory, and 
neuroimaging markers are used [1–3]. 
The ‘gold standard’ clinical rating scale for PD, and the one 
most commonly used, is the Unified Parkinson’s Disease Rating 
Scale (UPDRS) introduced in the 1980s [4], with its revised 
version known as MDS-UPDRS available from 2008 [5]. 
The MDS-UPDRS is composed of four sections: Part I: 
Non-Motor Experiences of Daily Living, has six rater-based 
items and seven for patient self-assessment; Part II: Motor 
Experiences of Daily Living, with 13 patient-based items; Part 
III: Motor Examination, with 18 items (33 scores); and Part IV: 
Motor Complications, with six items covering dyskinesia and 
fluctuations assessment. Each item scores from 0 (normal) to 
4 (severe) and total scores are obtained from the sum of the 
corresponding item scores for each part. Differing from the 
previous version, the MDS-UPDRS is completed by a mix of 
both clinician-rated sections (Part 1A, Part 3 and Part 4) and 
patient- and/or caregiver-completed sections (Part 1B and 
Part 2), without direct input from the rater. 
The new version relies on more information coming di-
rectly from patient and caregiver, and so it is vital that they 
understand the questions, preferably in their mother tongue. 
For this reason, the MDS Rating Scales Programme sets 
a specific protocol to designate successful translation of non-
-English versions. We aimed to translate and validate a Polish 
version of the MDS-UPDRS scale, and to compare it to the 
original English language version. Herein, we present the scale 
translation and clinimetric testing results of the Polish version 
of the MDS-UPDRS.
Clinical rationale for the study
The MDS-UPDRS has become the ‘gold standard’ of cli-
nical assessment of PD patients. Being an expanded patient/ 
/caregiver-reported questionnaire means that it relies more 
on subjective information from the patient and/or his or her 
caregiver. The presented validation of the Polish translation 
of the MDS-UPDRS that is consistent with the English lan-
guage version, confirms its suitability for use, and guarantees 
obtaining results for research purposes and everyday clinical 
practice that are comparable across different languages.
Material
The participants were 355 PD patients recruited from the 
neurology departments in ten sites located in different parts 
of Poland (two in Katowice, two in Krakow, one in Wroclaw, 
three in Warsaw, one in Gdansk, and one in Lodz). At each 
site experienced Polish movement disorder specialists were 
recruited to examine Polish-speaking PD patients of all ages, 
and at all disease Hoehn & Yahr stages.
Methods
Translation of the MDS-UPDRS
The MDS Rating Scales Programme has prepared a well-
-defined protocol, with objective criteria for translation and 
validation of non-English versions of the MDS-UPDRS in or-
der to have an “official MDS translation” in a foreign language. 
The process of developing an officially approved translation of 
the MDS-UPDRS involves four steps: (1) translation and inde-
pendent back-translation; (2) cognitive pretesting to establish 
that the translation is clear and comfortably administered 
by native-speaker raters and understood by native-speaker 
patients; (3) field testing in the native language using a large 
sample of PD patients; and (4) full clinimetric testing [6].
The Polish version validation was performed as follows: 
firstly, the MDS-UPDRS was translated into Polish by a team 
of Polish-speakers who were fluent in English, and who were 
physicians and specialists in movement disorders. This team 
was led by Dr. Joanna Siuda, and Prof. Grzegorz Opala. It was 
then back-translated into English by colleagues fluent in En-
glish and Polish and who had not been involved in the original 
translation. Finally, it was reviewed by a team of American 
experts, led by Profs. Christopher Goetz and Glenn Stebbins, 
Results. The Polish version of the MDS-UPDRS showed satisfactory clinimetric properties. The internal consistency of the Po-
lish version was satisfactory. In the confirmatory factor analysis, all four parts had greater than 0.90 comparative fit index (CFI) 
compared to the original English MDS-UPDRS. Explanatory factor analysis suggested that the Polish version differed from the 
English version only within an acceptable range. 
Conclusions and clinical implications: The Polish version of the MDS-UPDRS meets the requirements to be designated as the 
Official Polish Version of the MDS-UPDRS, and is available on the MDS web page. We strongly recommend using the MDS-UPDRS 
instead of the UPDRS for research purposes and in everyday clinical practice.
Key words: MDS-UPDRS, Parkinson’s Disease, rating scale, validation, translation
(Neurol Neurochir Pol 2020; 54 (5): 417–425)
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who had been involved in the development of the original 
English language version [7].
Cognitive pretesting
Cognitive pretesting is a qualitative approach to assessing 
instrument completion in terms of task difficulty for exami-
ner and respondent, and respondent interest, attention span, 
discomfort, and comprehension [8]. Where differences were 
observed between the back-translated Polish version and the 
English version, items were selected for cognitive pretesting 
along with questions that were identified in cognitive testing of 
the English version. Questions included in cognitive pretesting 
were: Cognitive Impairment, Anxious Mood, Handwriting, 
Freezing, Hand Movements, Arising from Chair, Time Spent 
with Dyskinesia, and Functional Impairment of Dyskine-
sia. Based on the results of the initial cognitive pretesting, 
other round(s) of translation, back-translation and cognitive 
pretesting could be required. Once cognitive pretesting was 
completed and no problems had been noted, the final trans-
lation was obtained.
Factor analysis
M-plus Version 7.4 was used to do the primary confirma-
tory and secondary exploratory factor analyses, as the variables 
are categorical [9]. We used an unweighted least squares (ULS) 
approach to factor estimation that minimises the sum of squa-
red differences between observed and estimated correlation 
matrices, not counting diagonal elements. To assist in inter-
pretation of the factors, we used an orthogonal CF-VARIMAX 
rotation that constrains the factors to be uncorrelated. 
The sample size for the translation study was based on 
the need for five subjects per item of the questionnaire in 
order to perform the statistical analysis [10]. Because there 
are 65 items on the MDS-UPDRS, a sample of at least 350 was 
required. Any participants with missing values within a Part 
were deleted from analysis of that Part only. Thus, the sample 
size from Part to Part could vary. 
Primary analysis
For the primary analysis of the Polish data, we conducted 
a confirmatory factor analysis (CFA) to determine whether the 
factor structure for the English language MDS-UPDRS could be 
confirmed in data collected using the Polish translation [11, 12]. 
This was the primary question of interest. The CFA was con-
ducted separately for MDS-UPDRS Parts I to IV, with the 
Polish data constrained to fall into the factors defined in the 
English language data. We evaluated the CFA results based on 
the Comparative Fit Index (CFI). According to the protocol, to 
establish a successful translation and to designate that trans-
lation as an official MDS translation of the MDS-UPDRS, it 
is required that the CFI for each Part (I–IV) of the translated 
MDS-UPDRS be 0.90 or greater relative to the English langua-
ge version. Mean and variance-adjusted weighted least square 
(WLSMV) estimator is used to confirm model fit.
Secondary analysis
As a secondary analysis, we conducted an exploratory 
factor analysis for the Polish version of the MDS-UPDRS 
Parts I-IV to explore the underlying factor structure without 
the constraint of a pre-specified factor structure. We used 
a SCREE plot to choose the number of factors to retain for 
each MDS-UPDRS Part. The subjective scree test [13] uses 
a scatter plot of eigenvalues plotted against their ranks with 
respect to magnitude, to extract as many factors as there are 
eigenvalues that fall before the last large drop (i.e. an ‘elbow’ 
shape) in the plot. Once the factors were chosen, an item 
was retained in a factor if the factor loading for that item 
was 0.40 or greater. To assist interpretation of the factors, an 
orthogonal CF-VARIMAX rotation was used which sets the 
factors to be uncorrelated.
Ethics
All patients gave written consent to participate. The 
anonymised patient data was transferred to the US team for 
analysis via a secure website. The programme for validation 
of the MDS-UPDRS Polish version was approved for all sites 
by the Ethics Committee of the Medical University of Silesia 
in Katowice (KNW/0022/KB/110/14). 
Results
Cognitive pretesting
Ten patients with Parkinson’s Disease and their exami-
ners were interviewed using the type of structured interview 
format typical for cognitive pretesting. No problems were 
identified for the raters. One of the 10 patients interviewed 
had difficulty comprehending the term “lightheadedness”, and 
another patient reported difficulty in reading the material for 
the self-report sections of the scale because the font was too 
small. No other patient-identified difficulties were noted. Slight 
modifications of the scale were recommended from this round 
of testing. Five patients completed a second round of cognitive 
pre-testing, and no difficulties were identified. The modified 
version of the scale was approved as the Official Working 
Draft of the Polish MDS-UPDRS for testing in a larger group 
of patients with PD.
Study population characteristics
The demographic characteristics of the sample are set out 
in Table 1. The sample included 355 Polish PD patients (mean 
age 64.0 ± 9.5 years, 56.9% males), with mean disease duration 
of 9.0 ± 5.9 years, who were examined using the MDS-UPDRS. 
They were all native Polish-speaking PD patients, white Cauca-
sians, and the majority had at least secondary education. The 
English language and Polish language cohorts were similar in 
terms of age and duration of disease. All Hoehn & Yahr stages 
(H&Y) were represented, with the majority (299 subjects, 
87.9%) being stages II and III. The distribution of H&Y was sig-
nificantly different between the two cohorts (p-value < 0.0001).
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Table 1. Demographic characteristics of study population
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Data available for 297*, 257**, 197***, 340****, and 284***** subjects in Polish PD population; SD — standard deviation, NA — not available
Table 2. Confirmatory factor analysis, CFA model fit




CFI = 0.90, RMSEA = 0.10  (355 patients)
CFI = 0.96, RMSEA = 0.06  (849 patients)




CFI = 0.97, RMSEA = 0.09 (355 patients)
CFI = 0.97, RMSEA = 0.09 (851 patients)
Part III: Motor examination (a 7-factor model)
Polish language
English language
CFI = 0.95, RMSEA = 0.10 (355 patients)
CFI = 0.95, RMSEA = 0.07 (801 patients)
Part IV: Motor complications (a 2-factor model)
Polish language
English language
CFI = 1.00, RMSEA = 0.16 (355 patients)
CFI = 1.00, RMSEA = 0.04 (848 patients)
CFI — comparative fit index, RMSEA — root mean square error of approximation; 
*Dopamine Dysregulation Syndrome (DDS) was not included in this analysis as it did not load on 
any factor
Primary analysis: Confirmatory Factor Analysis 
(CFA)
Table 2 displays the CFA models for each MDS-UPDRS 
Part. For all four Parts of the Polish MDS-UPDRS, the CFI, 
compared to the English-language factor structure, was 0.90 or 
greater. This confirmed that the pre-specified English factor 
structure was confirmed in the Polish dataset. 
Secondary analysis: Explanatory Factor Analysis 
(EFA)
EFA analysis for the Polish MDS-UPDRS dataset differed 
from the EFA of the English language dataset in some areas. 
From the SCREE plot we extracted: for Part I - two factors, for 
Part II - three components, for Part III - seven factors, and for 
Part IV - two factors. The SCREE plots are given in Figure 1. 
Table 3 shows the results of the Exploratory Factor Analysis 
for the English and Polish languages.  
For Part I, in contrast to the English language version of the 
MDS-UPDRS, Cognitive impairment and Hallucinations and 
psychosis loaded on factor 2, instead of factor 1. For Part II, Speech 
loaded on factor 3 instead of factor 1, Handwriting and Doing 
hobbies and other activities loaded on factor 2, which originally 
loaded on factor 1 in the English language. Eating tasks loaded 
on factor 1 instead of factor 2. Dressing and Freezing loaded on 
both factor 1 and factor 2, Hygiene and Turning in bed loaded 
on factor 2, which originally loaded on factor 3 in the English 
language. In Part III, Rigidity, neck did not load on any of the 
factors. Nine of the 33 items loaded on different factors in the 
two scales, and eight items loaded on more than one factor. Most 
of the items that loaded on different factors in the two versions 
also had cross-loadings on multiple factors. In Part IV, Time spent 
with dyskinesia did not load on any of the factors. Time spent in 
the OFF state and Functional impact of dyskinesia loaded on both 
factor 1 and factor 2 in the Polish Scale, having originally loaded 
on factor 1 and factor 2 respectively in the English language.
Discussion
The widespread use of the MDS-UPDRS instead of its 
predecessor the UPDRS, which was, and in some non-English 
speaking countries still is, the gold standard tool for the clinical 
assessment of PD patients, is to be recommended. The Move-
ment Disorders Society Rating Scales Programme leads the 
global translation effort of different assessment scales including 
the MDS-UPDRS. Currently, this programme includes 19 non-
English validated editions of the MDS-UPDRS. 
The overall factor structure of the Polish language ver-
sion of MDS-UPDRS was consistent with that of the English 
language version, confirming its suitability for use. A few 
isolated item differences in factor loadings were identified in 
the EFA of the Polish version. These small differences included 
some loading on more than one factor, while others loaded 
on a different factor, compared to the English MDS-UPDRS. 
For Part I, in contrast to the English language version of 
the MDS-UPDRS, Cognitive impairment and Hallucinations 
and psychosis loaded on factor 2 instead of factor 1. This 
might be explained by the fact that cognitive impairment in 
Polish society is still not well recognised, especially among 
the elderly where it is treated as a normal component of the 
ageing process, and so goes underreported. 
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Figure 1. Scree plots for English and Polish exploratory factor analyses
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Table 3. Comparison of English language and Polish Exploratory Factor structures for Parts I-IV of MDS-UPDRS
Factor Item     Item factor loading
  English*  Polish
Part I: Non-motor aspects of experiences of daily living
Factor 1      Percent variance                                           34.0 38.1
Daytime sleepiness 0.53 0.64
Sleep problems 0.35 0.55
Cognitive impairment                                                                                                                                      0.55 xxxx
Pain and other sensations                                                                0.43 0.67
 Hallucinations and psychosis 0.56 xxxx
Urinary problems                                                                           0.61 0.45
Constipation problems 0.46 0.53
Lightheadedness on standing 0.46 0.70
Fatigue 0.47 0.76
Factor 2 Percent variance 9.5 14.3
Depressed mood 0.81 0.84
Anxious mood 0.68 0.68
Apathy 0.55 0.83
Hallucinations and psychosis xxxx 0.44
Cognitive impairment                                                                                                                                      xxxx 0.52
Part II: Motor aspects of experiences of daily living
Factor 1       Percent variance 53.10 50.73
Speech 0.79 xxxx
Saliva and drooling                                                                       0.45 0.62
Chewing and swallowing                                                                0.60 0.65
Eating tasks                                                                                        xxxx 0.56
Dressing xxxx 0.40
Handwriting                                                                                  0.46 xxxx
Doing hobbies and other activities                                                0.46 xxxx
Walking and balance xxxx 0.47***
Freezing xxxx 0.41***
Factor 2       Percent variance 8.70 8.90
Eating tasks                                                                                        0.68 xxxx
Tremor                                                                                          0.43 0.56
Handwriting                                                                                  xxxx 0.94
Hygiene xxxx 0.75
Doing hobbies and other activities                                                xxxx 0.48
Dressing xxxx 0.49***
Turning in bed xxxx 0.59
Walking and balance xxxx 0.48***
Freezing xxxx 0.46***




Turning in bed 0.65 xxxx
Getting out of bed 0.73 0.49
Walking and balance 0.82 0.52
 Freezing 0.76 xxxx
Æ
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Factor Item     Item factor loading
  English*  Polish
Part III: Motor examination 
Factor 1 Percent variance 36.7 43.0
Speech 0.60 xxxx
Facial expression 0.54 xxxx
Arising from chair 0.80 0.76
Gait 0.87 0.81
Freezing of gait 0.83 0.75
Postural stability 0.80 0.65
Posture 0.70 0.73
Global spontaneity of movement 0.67 0.53
Leg agility, right leg xxxx 0.45***
Factor 2 Percent variance 15.3 14.7
Rest tremor amplitude, RUE 0.73 0.82
Rest tremor amplitude, LUE 0.71 0.79
Rest tremor amplitude, RLE 0.74 0.78
Rest tremor amplitude, LLE 0.70 0.78
Rest tremor amplitude, lip/jaw 0.60 0.48***
Constancy of rest tremor 0.88 0.78
Postural tremor, right hand xxxx 0.77
Postural tremor, left hand xxxx 0.76
Kinetic tremor, right hand xxxx 0.75***
Kinetic tremor, left hand xxxx 0.72***
Factor 3 Percent variance 6.6 8.5
Rigidity, neck 0.68 xxxx
Rigidity, RUE 0.73 0.58***
Rigidity, LUE 0.74 0.65***
Rigidity, RLE 0.80 0.65***
Rigidity, LLE 0.82 0.70***
Factor 4 Percent variance 6.2 5.1
Finger tapping, right hand 0.67 0.83
Hand movements, right hand 0.67 0.83
Pronation/supination, right hand 0.70 0.75
Leg agility, right leg xxxx 0.72***
Toe tapping, right foot xxxx 0.72
Rigidity, RUE xxxx 0.69***
Rigidity, RLE xxxx 0.56***
Factor 5 Percent variance 4.9 4.3
Finger tapping, left hand 0.67 0.81
Hand movements, left hand 0.70 0.85
Pronation/supination movements, left hand 0.65 0.73
Toe tapping, left foot xxxx 0.82
Leg agility, left leg xxxx 0.74
Rigidity, LUE xxxx 0.59***
Æ
423www.journals.viamedica.pl/neurologia_neurochirurgia_polska
Joanna Siuda et al., MDS-UPDRS Polish validation
Factor Item     Item factor loading
  English*  Polish
Part III: Motor examination
Rigidity, LLE xxxx 0.47***
Factor 6 Percent variance 4.5 3.7
Postural tremor, right hand 0.66 xxxx
Postural tremor, left hand 0.71 xxxx
Kinetic tremor, right hand 0.81 0.44***
Kinetic tremor, left hand 0.81 0.44***
Factor 7 Percent variance 3.3 2.8
Toe tapping, right foot 0.65 xxxx
Toe tapping, left foot 0.62 xxxx
Leg agility, right leg 0.62 xxxx
Leg agility, left leg 0.60 xxxx
Rest tremor amplitude, lip/jaw xxxx 0.47***
Speech xxxx 0.67
Facial expression xxxx 0.76
Part IV: Motor complications  
   Factor 1  Percent variance 63.9 67.4
Time spent in the OFF state 0.87 0.62***
Functional impact of fluctuations 0.84 0.91
Complexity of motor fluctuations 0.82 0.94
Painful OFF state dystonia 0.5 0.92
Functional impact of dyskinesias xxxx 0.48***
   Factor 2 Percent variance 15.6 17.6
Time spent with dyskinesias 0.71 xxxx
Functional impact of dyskinesias 0.95 0.86
 Time spent in the OFF state xxxx 0.68
*Different version of M-Plus, and the factor loadings may vary slightly from published version; *** item load on more than one factor with factor loading ≥ 0.40; xxxx implies that the listed item did not load on 
the factor indicated
Moreover, PD patients may not recognise memory prob-
lems as part of a wide range of PD symptomatology, and 
thus do not report them. Another argument, raised by the 
team of MDS experts, is that a cognition item, assessed by 
a single screening question, has a weak correlation with the 
corresponding cognitive scales i.e. Addenbrooke’s Cognitive 
Examination, ACE, Scales for Outcome of Parkinson’s Disease-
cognitive scale, SCOPA-COG, and Frontal Assessment Battery, 
FAB [14]. In regards to Hallucination and psychosis, rarely re-
ported in the studied population (301 subjects; 84.8% reported 
no psychotic problems), the information mainly came from 
PD patients, and only rarely was the interview conducted in 
the presence of the patient’s caregiver. Caregivers can be very 
good sources of information, especially when we are looking 
for information about non-motor symptoms of Parkinson’s 
Disease, which possibly go unnoticed by patients. 
For Part II, Speech loaded on factor 3 instead of factor 
1, and the majority of patients (231 subjects; 65.1%) was as-
sessed as either having no or minimal problems with speech. 
Handwriting and Doing hobbies and other activities loaded on 
factor 2, which originally loaded on factor 1 in the English 
language. Probably due to cultural differences, Polish PD 
patients tend to refer to hobbies and other activities done for 
pleasure in a more practical manner than do patients from 
English-speaking parts of the world. On the other hand, it has 
been demonstrated previously on a large multi-cultural and 
multi-language population that the MDS-UPDRS is effective 
in capturing parkinsonism, and is not highly influenced by 
gender, age, or race/ethnicity [15]. 
Nowadays, we tend to do less handwriting, and it is pos-
sible that patients do not pay much attention to this activity as 
long as they still have a legible signature. Eating tasks loaded 
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on factor 1 instead of factor 2, Dressing loaded on both factor 
1 and factor 2. Hygiene loaded on factor 2, which originally 
loaded on factor 3 in the English language. Walking and bal-
ance loaded on all three factors, unlike the English version 
that loaded only on factor 3. A possible explanation here 
is that independence is very important to our PD patients; 
they do not want anyone to help them unless it is absolutely 
necessary; and being able to dress, bathe, eat, or walk with-
out assistance is for them a determinant of a good quality 
of everyday life. 
In Part III, Rigidity, neck did not load on any of the factors, 
even though 219 (61.7%) patients reported it. Resting tremor 
of the upper limbs loaded in factor 2 in both the English and 
the Polish versions, but Postural and kinetic tremor of both 
upper limbs loaded in factor 2 in the Polish version while 
being only factor 6 in the English language version. This can 
be explained by cultural differences between English- and 
Polish-speaking societies, by the fact that tremor is an easily 
recognisable symptom, and because for many of our patients 
it is embarrassing, especially in social situations. In the Polish 
version, Toe tapping and leg agility on the right side loaded in 
factor 4, and Toe tapping and leg agility on the left side loaded 
on factor 5, unlike the English version in which these items 
loaded only in factor 7. Here again, bradykinesia in the lower 
limbs, probably causing gait problems, makes a patient less 
independent in their everyday life.
In Part IV, most items loaded on factor 1 in both language 
versions, underlining the importance of motor complications. 
There was one exception: in the Polish version Time spent with 
dyskinesia did not load on any of the factors, possibly because 
more than half (202 subjects, 56.9%) of PD patients reported 
having no dyskinesia. On the other hand, Functional impact 
of dyskinesia and Time spent in the OFF state loaded on both 
factor 1 and factor 2 in the Polish version. This confirms that 
levodopa-induced motor complications significantly impact 
upon patient well-being, and are related to an impaired health-
related quality of life (HRQoL) [16].  
We are aware that this study has some limitations related to 
potential sample selection bias. The data comes from high ref-
erence neurology clinics specialising in movement disorders, 
and it does not represent the general PD patient population 
in Poland. In addition, the distribution of patients showed 
a predominance of patients in early Hoehn & Yahr stages, 
with very few patients in advanced stages (only four subjects 
in H&Y stage V; 1.12%), and most patients (284 subjects, 80%) 
were examined in the ON state. Furthermore, the assessment 
was based mainly on patients’ responses, although caregivers 
may have valuable input into clinical evaluation, especially 
with regard to  non-motor symptoms [17].    
Conclusions and clinical implications: 
The overall factor structure of the Polish version was 
consistent with that of the English version based on the high 
CFIs for all four parts of the MDS-UPDRS in the confirma-
tory factor analysis (all CFI ³ 0.90). The Polish MDS-UPDRS 
was confirmed to share a common factor structure with the 
English version. 
Therefore, the MDS-UPDRS Polish version was designated 
as the Official Polish version of the MDS-UPDRS and is avail-
able from the MDS website  (https://www.movementdisorders.
org/MDS-Files1/Education/Rating-Scales/MDS-UPDRS_Pol-
ish_Official_Translation_FINAL.pdf).
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